Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
- PMID: 23245607
- PMCID: PMC6350784
- DOI: 10.1016/S0140-6736(12)61729-2
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Erratum in
- Lancet. 2013 Feb 23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added]
Abstract
Background: Non-fatal health outcomes from diseases and injuries are a crucial consideration in the promotion and monitoring of individual and population health. The Global Burden of Disease (GBD) studies done in 1990 and 2000 have been the only studies to quantify non-fatal health outcomes across an exhaustive set of disorders at the global and regional level. Neither effort quantified uncertainty in prevalence or years lived with disability (YLDs).
Methods: Of the 291 diseases and injuries in the GBD cause list, 289 cause disability. For 1160 sequelae of the 289 diseases and injuries, we undertook a systematic analysis of prevalence, incidence, remission, duration, and excess mortality. Sources included published studies, case notification, population-based cancer registries, other disease registries, antenatal clinic serosurveillance, hospital discharge data, ambulatory care data, household surveys, other surveys, and cohort studies. For most sequelae, we used a Bayesian meta-regression method, DisMod-MR, designed to address key limitations in descriptive epidemiological data, including missing data, inconsistency, and large methodological variation between data sources. For some disorders, we used natural history models, geospatial models, back-calculation models (models calculating incidence from population mortality rates and case fatality), or registration completeness models (models adjusting for incomplete registration with health-system access and other covariates). Disability weights for 220 unique health states were used to capture the severity of health loss. YLDs by cause at age, sex, country, and year levels were adjusted for comorbidity with simulation methods. We included uncertainty estimates at all stages of the analysis.
Findings: Global prevalence for all ages combined in 2010 across the 1160 sequelae ranged from fewer than one case per 1 million people to 350,000 cases per 1 million people. Prevalence and severity of health loss were weakly correlated (correlation coefficient -0·37). In 2010, there were 777 million YLDs from all causes, up from 583 million in 1990. The main contributors to global YLDs were mental and behavioural disorders, musculoskeletal disorders, and diabetes or endocrine diseases. The leading specific causes of YLDs were much the same in 2010 as they were in 1990: low back pain, major depressive disorder, iron-deficiency anaemia, neck pain, chronic obstructive pulmonary disease, anxiety disorders, migraine, diabetes, and falls. Age-specific prevalence of YLDs increased with age in all regions and has decreased slightly from 1990 to 2010. Regional patterns of the leading causes of YLDs were more similar compared with years of life lost due to premature mortality. Neglected tropical diseases, HIV/AIDS, tuberculosis, malaria, and anaemia were important causes of YLDs in sub-Saharan Africa.
Interpretation: Rates of YLDs per 100,000 people have remained largely constant over time but rise steadily with age. Population growth and ageing have increased YLD numbers and crude rates over the past two decades. Prevalences of the most common causes of YLDs, such as mental and behavioural disorders and musculoskeletal disorders, have not decreased. Health systems will need to address the needs of the rising numbers of individuals with a range of disorders that largely cause disability but not mortality. Quantification of the burden of non-fatal health outcomes will be crucial to understand how well health systems are responding to these challenges. Effective and affordable strategies to deal with this rising burden are an urgent priority for health systems in most parts of the world.
Funding: Bill & Melinda Gates Foundation.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflicts of interest
C E Canter has worked as an Optum Health consultant, Blue Cross Blue Shield consultant, and received Berlin Heart Honoraria and travel fees. E R Dorsey has received payments for consulting services from Lundbeck and Medtronic and research support from Lundbeck and Prana Biotechnology. T Driscoll was supported in part by funding from the National Occupational Health and Safety Commission (now Safework Australia). M Ezzati chaired a session and gave a talk at the World Cardiology Congress (WCC), with travel cost reimbursed by the World Heart Federation. At the WCC, he also gave a talk at a session organised by PepsiCo with no financial or other remuneration. F Guillemin did a study on osteoarthritis epidemiology in an institution that received grants from public sources: Assurance-Maladie (CNAMTS) InVS, Inserm, CHU de Nancy, CHU de Nice, Conseil Regional de Lorraine, Societe Francaise de Negma-Lerads, Pfizer, Pierre Fabre Medicaments, Sanofi-Aventis France. H J Hoffman is a US Federal Government employee of the National Institutes of Health (NIH). P J Hotez reports holding several positions: Dean, National School of Tropical Medicine, Baylor College of Medicine; Director, Sabin Vaccine Institute Texas Children’s Hospital Center for Vaccine Development; and President, Sabin Vaccine Institute. He also is an inventor on several patents: 5,527,937 “Hookworm Anticoagulant”; 5,753,787 “Nucleic Acids for Ancylostoma Secreted Proteins”; 7,303,752 B2 “Hookworm vaccine”; 12/492,734 “Human Hookworm Vaccine”; 61/077,256 “Multivalent Anthelminthic Vaccine”; and PCT-20100701/0.20.5.18 “Malaria Transmission blocking vaccine”. G A Mensah is a former employee of PepsiCo. F Perez-Ruiz was an advisor for Ardea, Menarini, Novartis, Metabolex; was a member of the Speaker’s Bureau for Menarini, Novartis; an advisor for educational issues for Savient; led investigation grants for the Spanish Health Ministry, Hospital de Cruces Rheumatology Association; and was principal investigator in clinical trials for Ardea. G V Polanczyk has served as a speaker or consultant to Eli-Lily, Novartis, Janssen-Cilag, and Shire Pharmaceuticals, developed educational material for Janssen-Cilag, and received an independent investigator grant from Novartis and from the National Council for Scientific and Technological Development (CNPq, Brazil). L Rushton received honorarium for board membership of the European Centre for Ecotoxicology and Toxicology of Chemicals and received research grants to Imperial College London (as PI) from the European Chemical Industry Council (CEFIC) and CONCAWE (Conservation of Clean Air and Water Europe). J A Singh has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals, and Novartis. J A Singh is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s Guidelines Subcommittee of the Quality of Care Committee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. J A Singh is supported by research grants from the National Institutes of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), National Cancer Institute (NCI) and the Agency for Health Quality and Research Center for Education and Research on Therapeutics (CERTs) and is also supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA.
Figures
![Figure 1:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0001.gif)
![Figure 2:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0002.gif)
![Figure 3:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0003.gif)
![Figure 4:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0004.gif)
![Figure5:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0005.gif)
![Figure 6:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0006.gif)
![Figure 7:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0007.gif)
![Figure 8:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0008.gif)
![Figure 9:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0009.gif)
![Figure 10:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0010.gif)
![Figure 11:](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/6350784/bin/nihms-1005038-f0011.gif)
Comment in
-
Global burden of cardiovascular disease.Nat Rev Cardiol. 2013 Feb;10(2):59. doi: 10.1038/nrcardio.2012.194. Epub 2013 Jan 8. Nat Rev Cardiol. 2013. PMID: 23296068 No abstract available.
Similar articles
-
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7. Lancet. 2015. PMID: 26063472 Free PMC article. Review.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Lancet. 2017. PMID: 28919117 Free PMC article.
-
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.Lancet. 2024 May 18;403(10440):2133-2161. doi: 10.1016/S0140-6736(24)00757-8. Epub 2024 Apr 17. Lancet. 2024. PMID: 38642570 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. Lancet. 2018. PMID: 30496104 Free PMC article.
-
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993280 Review.
Cited by
-
Comparison between three methods of diode laser 810 nm, photodynamic therapy with laser 660 nm, and hypochlorite solution for disinfection of pulp canal of primary teeth.Dent Res J (Isfahan). 2024 Mar 26;21:23. eCollection 2024. Dent Res J (Isfahan). 2024. PMID: 38807661 Free PMC article.
-
Annual epidemiological and health insurance disease burden of hip osteoarthritis in Hungary based on nationwide data.BMC Musculoskelet Disord. 2024 May 23;25(1):406. doi: 10.1186/s12891-024-07513-y. BMC Musculoskelet Disord. 2024. PMID: 38783258 Free PMC article.
-
Association between chronic pain and dementia: a systematic review and meta-analysis.Eur J Ageing. 2024 May 22;21(1):17. doi: 10.1007/s10433-024-00812-2. Eur J Ageing. 2024. PMID: 38777965 Free PMC article. Review.
-
Exploration of the Changes in Facial Microbiota of Maskne Patients and Healthy Controls Before and After Wearing Masks Using 16 S rRNA Analysis.J Epidemiol Glob Health. 2024 May 21. doi: 10.1007/s44197-024-00240-6. Online ahead of print. J Epidemiol Glob Health. 2024. PMID: 38771488
-
Effects of co-application of tiotropium bromide and traditional Chinese medicine on patients with stable chronic obstructive pulmonary disease: a muilticenter, randomized, controlled trial study.Front Med (Lausanne). 2024 May 3;11:1289928. doi: 10.3389/fmed.2024.1289928. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38765259 Free PMC article.
References
-
- Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996; 274: 740–3. - PubMed
-
- Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet 1997; 349: 1347–52. - PubMed
-
- World Health Organization. The world health report 2000—Health systems: improving performance. 2010. http://www.who.int/whr/2000/en/whr00_en.pdf (accessed July 9, 2012).
-
- World Health Organization. The world health report 2001—Mental Health: New Understanding, New Hope. 2001. http://www.who.int/whr/2001/en/whr01_en.pdf (accessed June 25, 2012).
-
- World Health Organization. The world health report 2002— Reducing Risks, Promoting Healthy Life. 2002. http://www.who.int/whr/2002/en/whr02_en.pdf (accessed July 9, 2012).
Publication types
MeSH terms
Grants and funding
- 095009/WT_/Wellcome Trust/United Kingdom
- ES015459/ES/NIEHS NIH HHS/United States
- 085308/WT_/Wellcome Trust/United Kingdom
- DH_/Department of Health/United Kingdom
- T32 ES015459/ES/NIEHS NIH HHS/United States
- P30 ES000260/ES/NIEHS NIH HHS/United States
- K23 AG034236/AG/NIA NIH HHS/United States
- ES00260/ES/NIEHS NIH HHS/United States
- K08 HL089675/HL/NHLBI NIH HHS/United States
- G0901214/MRC_/Medical Research Council/United Kingdom
- ImNIH/Intramural NIH HHS/United States
- 092654/WT_/Wellcome Trust/United Kingdom
- 098045/WT_/Wellcome Trust/United Kingdom
- WT_/Wellcome Trust/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous